DK3999180T3 - Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid - Google Patents

Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid Download PDF

Info

Publication number
DK3999180T3
DK3999180T3 DK20753562.6T DK20753562T DK3999180T3 DK 3999180 T3 DK3999180 T3 DK 3999180T3 DK 20753562 T DK20753562 T DK 20753562T DK 3999180 T3 DK3999180 T3 DK 3999180T3
Authority
DK
Denmark
Prior art keywords
inden
oxadiazol
polymorphs
carboxamide
pyrazole
Prior art date
Application number
DK20753562.6T
Other languages
Danish (da)
English (en)
Inventor
Norma TOM
Matthew Pfeiffer
Denise Andersen
Qi Gao
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3999180(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Application granted granted Critical
Publication of DK3999180T3 publication Critical patent/DK3999180T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK20753562.6T 2019-07-17 2020-07-16 Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid DK3999180T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875350P 2019-07-17 2019-07-17
PCT/US2020/042387 WO2021011807A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Publications (1)

Publication Number Publication Date
DK3999180T3 true DK3999180T3 (da) 2024-05-21

Family

ID=71995103

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20753562.6T DK3999180T3 (da) 2019-07-17 2020-07-16 Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid

Country Status (25)

Country Link
US (1) US20220315571A1 (cg-RX-API-DMAC10.html)
EP (2) EP4487911A1 (cg-RX-API-DMAC10.html)
JP (2) JP7624431B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220084008A (cg-RX-API-DMAC10.html)
CN (3) CN118908951A (cg-RX-API-DMAC10.html)
AU (1) AU2020313965B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022000494A2 (cg-RX-API-DMAC10.html)
CA (1) CA3144975A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000054A1 (cg-RX-API-DMAC10.html)
DK (1) DK3999180T3 (cg-RX-API-DMAC10.html)
ES (1) ES2980885T3 (cg-RX-API-DMAC10.html)
FI (1) FI3999180T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240713T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066891T2 (cg-RX-API-DMAC10.html)
IL (1) IL289875B1 (cg-RX-API-DMAC10.html)
LT (1) LT3999180T (cg-RX-API-DMAC10.html)
MX (1) MX2022000504A (cg-RX-API-DMAC10.html)
PH (1) PH12022550123A1 (cg-RX-API-DMAC10.html)
PL (1) PL3999180T3 (cg-RX-API-DMAC10.html)
PT (1) PT3999180T (cg-RX-API-DMAC10.html)
RS (1) RS65611B1 (cg-RX-API-DMAC10.html)
SI (1) SI3999180T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400224T1 (cg-RX-API-DMAC10.html)
TW (1) TWI865562B (cg-RX-API-DMAC10.html)
WO (1) WO2021011807A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) * 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP2024530111A (ja) * 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程

Also Published As

Publication number Publication date
IL289875B1 (en) 2026-05-01
CA3144975A1 (en) 2021-01-21
NZ784930A (en) 2025-03-28
IL289875A (en) 2022-03-01
EP4487911A1 (en) 2025-01-08
EP3999180B1 (en) 2024-05-08
JP2022540668A (ja) 2022-09-16
KR20220084008A (ko) 2022-06-21
TWI865562B (zh) 2024-12-11
CN114555590A (zh) 2022-05-27
CN118908951A (zh) 2024-11-08
ES2980885T3 (es) 2024-10-03
JP2025061484A (ja) 2025-04-10
HRP20240713T1 (hr) 2024-09-13
EP3999180A1 (en) 2022-05-25
MX2022000504A (es) 2022-02-10
US20220315571A1 (en) 2022-10-06
CN114555590B (zh) 2024-09-10
BR112022000494A2 (pt) 2022-03-03
PH12022550123A1 (en) 2022-12-19
JP7755090B2 (ja) 2025-10-15
PT3999180T (pt) 2024-06-25
AU2020313965B2 (en) 2026-06-18
AU2020313965A1 (en) 2022-03-03
CL2022000054A1 (es) 2022-10-07
LT3999180T (lt) 2024-08-26
JP7624431B2 (ja) 2025-01-30
PL3999180T3 (pl) 2024-09-23
WO2021011807A1 (en) 2021-01-21
RS65611B1 (sr) 2024-07-31
FI3999180T3 (fi) 2024-06-18
SMT202400224T1 (it) 2024-07-09
TW202116763A (zh) 2021-05-01
SI3999180T1 (sl) 2024-07-31
HUE066891T2 (hu) 2024-09-28
CN119119018A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
IL289875A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
IL289881A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide
CO2020009901A2 (es) Formas cristalinas novedosas
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
SI3464265T1 (sl) Polimorfi N-((3-fluoro-4-metoksipiridin-2-IL)metil)-3-(metoksimetil)- 1-((4-(2-oksopiridin-1-IL)metil)fenil)pirazol-4-karboksamida kot zaviralci kalikreina
IL256237A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
IL260403B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
DK3908584T3 (da) Krystalformer af 1-(1,2-dimethylpropyl)-n-ethyl-5-methyl-n-pyridazin-4-ylpyrazol-4-carboxamid
MA55019A (fr) Forme cristalline du monohydrate de 1-(1-oxo-1,2-dihydroisoquinoléin-5-yl)-5-(trifluorométhyl)-(2-(trifluorométhyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
ES2721280T3 (es) Nuevos inhibidores de la FYN quinasa
DK3286176T3 (da) Krystallinske former af 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
HUE066426T2 (hu) Dopamin D1 receptor pozitív allosztérikus modulátor fenil-3,4-dihidroizokinolin-2(1H)-il-etan-1-on származékok
HK40075684B (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
DK3978485T3 (da) Ny krystalform af 3-(4-(benzyloxy)fenyl)hex-4-inoinsyrederivat
DK3298006T3 (da) Antifungal 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorphenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl)benzamid eller et farmaceutisk acceptabelt salt deraf
HK40074727A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
DK3643704T3 (da) Nye mellemprodukter til fremstilling af remifentanil-hydrochlorid
UA111920C2 (uk) Амоній 2-(5-(феноксиметил)-1н-1,2,4-триазол-3-ілтіо)ацетат, що виявляє гіпоглікемічну активність
EP3906238A4 (en) IMPROVED PROCESS FOR PRODUCTION OF 5-(3-PYRIDYL)-2,2'-BITHIOPHENE (SENSIBILIZER)